UNSPSC 51422600: Combination glucocorticoids

This classification denotes combination drugs and preparations that consist of corticosteroids that affect carbohydrate metabolism or GLUCONEO-GENESIS, liver glycogen deposition, and elevation of BLOOD SUGAR, inhibit adrenocorticotropic hormone secretion, and possess anti-inflammatory activity, and which thefore bear the name GLUCO-CORTICOIDS or GLUCOCORTICOIDS. Typical combination glucocorticoid constituents are dexamethasone and lidocaine.

UNSPSC 51422600 Combination glucocorticoids is a Class code that nominally names corticosteroid pharmaceuticals, but the recent state and local opportunities tagged under it do not reflect glucocorticoid procurement. Instead, the code shows activity in emergency response and pharmacy benefit management services — specifically naloxone and drug deactivation systems procurement, and exploratory market research into direct-to-manufacturer pharmacy contracting models. The mismatch between the code's abstract name and what is actually being bought suggests either tagging inconsistency or scope drift in how this code is being applied in the field.

Activity under this code appears sparse and geographically limited. The identifiable recent opportunities originate from Seminole County, Florida (an IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023) and the Texas Health and Human Services Commission (an RFI posted April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs). Neither opportunity aligns with the code's glucocorticoid classification. The absence of recent glucocorticoid-specific solicitations and the presence of unrelated pharmaceutical-adjacent work suggest this code may not be actively used for its nominal commodity in current state and local procurement, warranting verification of code assignment before pursuing opportunities listed under it.